Navigation Links
Spectral diagnostics Raises $14 million and enters into strategic collaboration with BioMS Medical to commercialize treatment for sepsis
Date:12/17/2009

added to conventional therapy, significantly improved hemodynamics and organ dysfunction, and reduced 28-day mortality in patients with severe sepsis and septic shock in comparison to those patients in the conventional therapy group.

Terms of the Financing

Under the terms of the financing (the "Financing") the Company will issue 35,000,000 units of the Company (the "Units") at a price of $0.40 per Unit to BioMS and GrowthWorks WV Management Ltd. and certain of its affiliates (collectively, "GrowthWorks"), for aggregate gross proceeds of $14 million. Each Unit consists of one common share of the Company ("Common Share") and one half of one Common Share purchase warrant (each whole Common Share purchase warrant, a "Warrant") entitling the holder thereof to acquire one Common Share at a price of $0.60 per Common Share for a period of four years from Closing.

BioMS will invest $12 million to acquire 30,000,000 Units under the Financing, and following Closing will hold 30,000,000 Common Shares, representing approximately 48% of the issued and outstanding Common Shares, calculated on a non-diluted basis, after giving effect to the Proposed Transactions (as defined below). BioMS will also be issued 15,000,000 Warrants in the Financing. GrowthWorks will invest $2 million in the Financing.

In connection with the Financing, and as partial consideration for services performed, at Closing, the Company will also issue broker warrants to Desjardins Securities Inc., who acted as agent for the Financing, which will entitle them to acquire 1,050,000 Common Shares at an exercise price of $0.40 per Common Share, and a further 525,000 Common Shares at an exercise price of $0.60 per Common Share, in each case, for a period of four years from Closing.

At Closing, the Company has also agreed to issue 2,890,625 Common Shares to GrowthWorks at a deemed price of $0.40 per Common Share as full repayment and final settlement of a non-in
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. First Spaceborne Hyperspectral Imager Will Use QImaging Rolera-MGi EMCCD Camera
2. Spectral appoints new board member
3. Spectral announces second quarter 2009 results
4. Spectral announces publication demonstrating Toraymyxin(TM) significantly reduces mortality from sepsis in prospective controlled trial
5. Spectral announces first quarter 2009 results
6. Spectral announces presentations at the 29TH International Symposium on Intensive Care and Emergency Medicine focusing on the role of endotoxin
7. Spectral announces 2008 financial results
8. Spectral signs exclusive license agreement to bring sepsis therapeutic to the U.S. market
9. Surface plasmon resonances of metal nanoparticles in array can have narrower spectral widths
10. Spectral announces third quarter 2008 results
11. Spectral to bring anti-sepsis therapy to the U.S. market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... Day 180 List of Outstanding Issues (LOI) from the ... Use (CHMP) for the NB32 Marketing Authorization Application (MAA). ... an investigational drug candidate being evaluated for weight loss. ... 120 time point were adequately addressed by the Company ...
(Date:7/30/2014)... , July 30, 2014  AtheroNova Inc. ... research and development of compounds to safely regress ... today announces that its partner, CardioNova, has accomplished ... clinical trial with AtheroNova,s lead compound, AHRO-001.  This ... the AHRO-001 Phase 1 safety trial completed in ...
(Date:7/30/2014)... CA (PRWEB) July 30, 2014 ... from the U.S. Environmental Protection Agency (EPA). This ... in developmental toxicity models, including tests designed to ... formation and the formation of connections between neurons ... of neurodifferentiation and synapse formation by environmental pollutants ...
(Date:7/29/2014)... 30, 2014 SoundConnect , ... company, is proud to announce the strategic additions ... in their Boston, Charleston and Atlanta offices. ... increased demand for hosted solutions, collaboration and mobility ... reduce cost. , SoundConnect was founded in 2004, ...
Breaking Biology Technology:Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3SoundConnect Organization and Culture is Evolving 2
... Preclinical Research at Upcoming Conferences, CALGARY, Sept. ... ONCY) today announced the participation of five of ... conferences,through November 15, 2008 covering clinical trial results ... time for Oncolytics as we begin to share ...
... Surgeons with No-Touch,Surgical Tool For Precision Brain ... 22 OmniGuide, Inc., announced,today the introduction ... flexible,CO2 laser scalpel for neurosurgery. The BeamPath ... microsurgical tool for various central,nervous system (CNS) ...
... their health, yet up to ... elevated risk for cardiovascular events, yet 20 percent, of those have not spoken ... ... A new survey of men and,women age 40 and older in the United ...
Cached Biology Technology:Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Clinical Trial 2Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Clinical Trial 3OmniGuide Introduces The BeamPath Neuro(TM): A CO2 Laser Fiber for Brain And Spine Surgery 2OmniGuide Introduces The BeamPath Neuro(TM): A CO2 Laser Fiber for Brain And Spine Surgery 3Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Aren't 'Risk Takers' 2Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Aren't 'Risk Takers' 3Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Aren't 'Risk Takers' 4Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Aren't 'Risk Takers' 5Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Aren't 'Risk Takers' 6Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Aren't 'Risk Takers' 7
(Date:7/30/2014)... roughly 3,000 pieces is still in its infant stage. ... be of major significance. "Amazingly often, we are findingin ... amber that we found in Baltic amber," explained Bonn ... amber comes from the Baltic Sea region, which is ... are, e.g., the coastal regions of Mecklenburg, Poland and ...
(Date:7/30/2014)... the first high-resolution map of the carbon stocks ... Per. The new and improved methodology used to ... future market-based carbon economies. The new carbon ... and it provides the critical input to studies ... use, and enforcement purposes. The technique includes the ...
(Date:7/29/2014)... of Bristol,s Nutrition and Behaviour Unit (NBU) has looked ... planning meals. , The research, to be presented at ... (SSIB 2014) in Seattle, USA this week [29 July ... team was led by Professor Jeff Brunstrom, and is ... part of a Biotechnology and Biological Sciences Research Council ...
Breaking Biology News(10 mins):Chinese mosquitos on the Baltic Sea 2Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3
... of branching - wild varieties of the plant Arabidopsis ... of this small mustard plant, a favorite of many ... strains from the polar circle or the subtropics, from ... first time by research teams from Tübingen, Germany, and ...
... discovered one way the p53 gene does what it's known ... in the June 8 issue of Molecular Cell. , ... a microRNA called miR-34a that participates in p53's uncanny ability ... genes in their nuclei. MicroRNAs are small chains of ribonucleic ...
... Aspirin didn’t pan out. Neither did two other potential ... desert shrub is now a front- runner in ongoing ... to inhibit inflammation, cancer and other destructive processes, can ... the annual meeting of the American Aging Association, University ...
Cached Biology News:One species, many genomes 2One species, many genomes 3Common cancer gene sends death order to tiny killer 2Agent slows aging in mice 2
... Concept in Microarrays: Biomedical Photometrics Inc. (Waterloo, ... (Jena, Germany) have collaborated to develop a ... System. The DNAscope AT is based ... DNAscope AT automatically reads up to six ...
... Localization in Early Drug Development with Imaging ... essential drug compound localization data in early ... imaging mass spectrometry service maps unlabeled ... images so you can localize drugs and ...
... provides a comprehensive kinase analysis service ... (PKS) peptide microarrays synthesized on Paraflo ... profiling, quantitative measurement of kinase kinetic ... comprehensive service includes preparation of your ...
Best pricing for 100mg-1.0g scales. Phosphopeptides are our specialty....
Biology Products: